BioCentury | Sep 11, 2020
Product Development

Pfizer’s MacKenzie: Other diseases deserve the same acceleration as COVID-19: a BioCentury audio interview

Pfizer’s Rod MacKenzie says the collaborations and accelerated timelines taking place during COVID-19 are causing introspection in pharmas for how they operate, and for how they can push for regulators...
BioCentury | Sep 11, 2020
Product Development

Hamburg on how COVID-19 collaboration models could propel drug development for public health priorities: a BioCentury audio interview

The extraordinary collaboration and commitment on the part of biopharma companies and governments that COVID-19 has inspired should serve as models for addressing unmet medical needs after the crisis has passed, Margaret Hamburg, who served...
BioCentury | Sep 11, 2020
Product Development

COVID-19 should spur massive investment in science and technology, Regeneron’s Yancopoulos says: a BioCentury audio interview

In addition to preparing for future pandemics, the U.S. should increase its investments in science and technology by orders of magnitude to head off crippling onslaughts of disease, Regeneron’s George Yancopoulos told BioCentury. In a...
BioCentury | Sep 5, 2020
Product Development

Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis

Gilead, HiFiBiO partner on AMLHiFiBiO Therapeutics has closed its second partnership with the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD), this time using its antibody and single-cell profiling technology to discover targets for...
BioCentury | Sep 2, 2020
Management Tracks

Career officials Rebello, Felberbaum to lead FDA’s communications

Former FDA commissioners Scott Gottlieb and Robert Califf tweeted their praise Tuesday of the appointment of two long-time FDA officials to head the agency’s communications.  Heidi Rebello will become FDA’s acting associate commissioner for external...
BioCentury | Jul 16, 2020
Politics, Policy & Law

BIO expresses support for Fauci, blasts attacks on science

BIO President and CEO Michelle McMurry-Heath has put the organization on record as supporting Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases, and called in a statement for an end to...
BioCentury | Jul 3, 2020

July 2 Quick Takes: Novartis to ante up $678M in settlement; plus Zai, Neoleukin, Base Genomics, Sarepta-Hansa, Dr. Reddy-Fujifilm

Novartis to pay $678M in kickbacks settlement Novartis AG (NYSE:NVS; SIX:NOVN) will pay $678 million and, under a corporate integrity agreement, conduct its speaker programs virtually for the next five years after the pharma reached...
BioCentury | May 22, 2020
Politics, Policy & Law

Woodcock steps away from CDER for Operation Warp Speed; Marks back to CBER

In a major reorganization intended to better align FDA’s activities with the national effort to develop COVID-19 countermeasures, Janet Woodcock is temporarily stepping away from her position as director of FDA’s Center for Drug Evaluation...
BioCentury | May 14, 2020
Management Tracks

Former GSK exec Slaoui to lead Trump’s ‘Warp Speed’ vaccine initiative

BIO President and CEO Jim Greenwood welcomed the appointment Wednesday of vaccine veteran Moncef Slaoui as head of the Trump administration’s Operation Warp Speed initiative, which is intended to fast-track COVID-19 vaccine development. Slaoui, now...
BioCentury | May 6, 2020
Politics, Policy & Law

Bright shines harsh light on America’s COVID-19 preparedness, FDA’s independence

This story was updated to reflect additional comments from FDA that were provided after publication of the initial version. Cronyism has crippled America’s pandemic response, enriching undeserving entrepreneurs and politically potent consultants who siphoned funds...
Items per page:
1 - 10 of 915